Please login to the form below

Not currently logged in

Dr Robert Kim joins Apellis as chief medical officer

Brings experience from Novartis, Genentech and GSK

Apellis Pharmaceuticals Dr Robert KimDr Robert Kim has taken up a role at Apellis Pharmaceuticals as chief medical officer, bringing to the US clinical stage immunotherapy company experience from Novartis, Genentech and GSK.

While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.

Meanwhile, at he served at GSK as VP of clinical ophthalmology, helping build its early stage clinical pipeline, and was VP and head of pharmaceutical product development at Novartis/Alcon.

Most recently he was at retina startup Vision Medicines, where he was chief medical officer and head of R&D.

In his new role at Louisville, Kentucky-based Apellis Dr Kim will help the company optimise its drug development strategy as its clinical programmes progress toward late-stage clinical testing.

Apellis CEO Cedric Francois said: "Bob is an experienced clinical drug developer whose deep knowledge and experience will help us prepare for our confirmatory trials in geography atrophy and the further expansion of our exciting clinical pipeline centred on the inhibition of complement factor C3."

11th August 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...